TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 5.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 69,390 shares of the biopharmaceutical company’s stock after acquiring an additional 3,610 shares during the period. The Manufacturers Life Insurance Company’s holdings in TG Therapeutics were worth $2,692,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Eudaimonia Partners LLC grew its position in shares of TG Therapeutics by 94.0% during the 1st quarter. Eudaimonia Partners LLC now owns 904 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 438 shares during the period. Benjamin F. Edwards & Company Inc. lifted its stake in TG Therapeutics by 333.3% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 1,300 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 1,000 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in TG Therapeutics by 116.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $89,000 after buying an additional 1,233 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in TG Therapeutics by 76.9% in the 1st quarter. Rockefeller Capital Management L.P. now owns 2,300 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,000 shares in the last quarter. Finally, First Mercantile Trust Co. lifted its stake in TG Therapeutics by 40.7% in the 2nd quarter. First Mercantile Trust Co. now owns 2,767 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 801 shares in the last quarter. Hedge funds and other institutional investors own 67.14% of the company’s stock.

TGTX opened at $32.80 on Thursday. The company’s 50 day simple moving average is $28.65 and its two-hundred day simple moving average is $35.21. TG Therapeutics, Inc. has a 1-year low of $21.06 and a 1-year high of $56.74. The firm has a market capitalization of $4.64 billion, a price-to-earnings ratio of -12.06 and a beta of 2.11.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Sunday, August 1st. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.11). TG Therapeutics had a negative return on equity of 90.75% and a negative net margin of 14,271.13%. The business had revenue of $1.55 million during the quarter, compared to analysts’ expectations of $3.69 million. On average, sell-side analysts forecast that TG Therapeutics, Inc. will post -2.37 EPS for the current year.

TGTX has been the topic of a number of research reports. HC Wainwright decreased their price target on shares of TG Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research note on Monday, August 2nd. Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, September 29th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $69.25.

TG Therapeutics Profile

TG Therapeutics, Inc engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Recommended Story: What is Cost of Goods Sold (COGS)?

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.